Arihant Capital Markets Regulatory Approval

Financial Results

Arihant Capital Markets Q2 FY27 Results: Net Profit ₹20.9 Cr, Up 59.5% YoY

Arihant Capital Markets Ltd reported revenue from operations of ₹75.8 Cr (+33.0% YoY) and net profit of ₹20.9 Cr (+59.5% YoY) for Q2 FY27.

Key figure

Net profit ₹20.9 Cr · +59.5% YoY

Board Meeting Date

Arihant Capital Markets Board Meeting Date

Arihant Capital Markets will hold a board meeting on 30-Oct-2026 to consider unaudited standalone and consolidated results for the quarter and half year ended 30-Sep-2026. The trading window is closed from 01-Oct-2026.

Other Announcement

Arihant Capital Markets Other Announcement

Arihant Capital Markets Ltd submitted its quarterly shareholding pattern report for the period ended September 30, 2026, as required under SEBI regulations.

Annual General Meeting

Arihant Capital Markets Annual General Meeting

Arihant Capital Markets Ltd held its 34th Annual General Meeting, approving financial statements for FY2026 and declaring a dividend of Rs. 0.50 per share.

Annual General Meeting

Arihant Capital Markets Annual General Meeting

Arihant Capital Markets Limited issued notice for its Annual General Meeting scheduled for 26-Sep-2026. Shareholders will consider financial statements, dividends, and director re-appointment.

Annual Report

Arihant Capital Markets Annual Report

Arihant Capital Markets Limited has submitted its Integrated Annual Report for the fiscal year 2025-26 along with the notice for its 34th Annual General Meeting.

Regulatory ApprovalDr. Reddy's Laboratories Ltd DRREDDYAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Dr. Reddy's Laboratories Regulatory Approval

Dr. Reddy's Laboratories received marketing authorization from Brazil's ANVISA for its generic semaglutide injection. The approval targets Brazil's diabetes market, estimated at approximately USD 244.6 million.

Regulatory ApprovalAlembic Pharmaceuticals Ltd APLLTDAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Alembic Pharmaceuticals Regulatory Approval

Alembic Pharmaceuticals received USFDA final approval for its generic Olopatadine Hydrochloride Ophthalmic Solution 0.7% ANDA. The product's US market is estimated at $20 million, per IQVIA.

Regulatory ApprovalEmmbi Industries Ltd EMMBIAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Emmbi Industries Regulatory Approval

SEBI exempted the Makrand and Rinku Appalwar business trusts from SAST takeover rules for an internal family share transfer. Control and promoter shareholding remain unchanged.

Regulatory ApprovalBliss GVS Pharma Ltd BLISSGVSAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Bliss GVS Pharma Regulatory Approval

Bliss GVS Pharma's UK subsidiary Asterisk Lifesciences received MHRA marketing authorisation for Mesalazine 1g Suppositories. The approval lets the subsidiary market the product in the UK.

Regulatory ApprovalJohn Cockerill India Ltd COCKERILLAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

John Cockerill India Regulatory Approval

John Cockerill India received Reserve Bank of India approval for acquiring shares of John Cockerill Metals International SA. This allows the company to proceed with the share-swap acquisition.

Regulatory ApprovalGland Pharma Ltd GLANDAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Gland Pharma Regulatory Approval

Gland Pharma received USFDA approval for Methylprednisolone Acetate Injectable Suspension USP in multiple vial formats. The product is bioequivalent to Pfizer's Depo-Medrol in a ~$214M US market.